Allot Announces the Appointment of Eyal Harari as Chief Executive Officer
Hod Hasharon, Israel, May 06, 2024 (GLOBE NEWSWIRE) — Allot Ltd. (NASDAQ: ALLT, TASE: ALLT), a leading global provider of […]
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
MIAMI, May 06, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with […]
N2OFF: Save Foods to Target California’s Hemp Market
More than half of US hemp flower grown in California recently received Pre-Harvest Regulatory Approval in California allowing Save Foods […]
Skyward Specialty Announces Secondary Offering of Its Common Stock
HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) — Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a […]
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 […]
Inari Medical to Participate in the 2024 Bank of America Securities Healthcare Conference
IRVINE, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a […]
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic […]
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a […]
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment […]
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to […]
